The invention concerns the use and the production of non-neurotoxic plasminogen activating factors, derived, for example, from the common vampire Desmodus rotundus (DSPA), for therapeutic treatment of stroke in humans. The invention provides a novel therapeutic base for treating stroke in humans.

This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.

The present invention is directed to methods of treatment of airway obstruction associated with fibrin-containing cast formation by administering a fibrinolytic agent.

The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

Systems and methods are provided for ultrasound-based microbubble-assisted or nanobubble-assisted theragnosis, treating, ameliorating, or preventing one or more vascular diseases. In particular, systems and methods are provided for transcutaneous imaging of blood vessels located at various depths (including deeper regions) from the skin surface using ultrasound, and/or performing localized gene therapy using ultrasound at or near the imaged blood vessels. The systems and methods described herein may be used for diagnosis and/or treatment of vascular disorders, including but not limited to DVT, PE, venous thromboembolism (VTE) that includes DVT and PE, where PE usually follows DVT, post-thrombotic syndrome, embolic strokes, embolic heart attacks, and combinations thereof.

Provided herein are methods for safe and effective thrombolysis in therapy for human subjects with symptoms of a potential stroke or acute myocardial infarction (AMI) using a sequential administration of a low dose bolus of human tissue plasminogen activator (tPA) followed by an infusion of a mutant form of human pro-urokinase (proUK).